CSTL Castle Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSTL

Price (delayed)

$22.51

Market cap

$598.22M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$488.58M

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently ...

Highlights
CSTL's revenue is up by 46% YoY and by 11% from the previous quarter
The gross profit has grown by 34% YoY and by 9% from the previous quarter
The net income has dropped by 115% year-on-year and by 27% since the previous quarter
CSTL's EPS has dropped by 108% year-on-year and by 26% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.castlebiosciences.com
Peers: OCUP

Key stats

What are the main financial stats of CSTL
Market
Shares outstanding
26.58M
Market cap
$598.22M
Enterprise value
$488.58M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.49
Price to sales (P/S)
4.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
Earnings
Revenue
$137.04M
EBIT
-$68.89M
EBITDA
-$58.34M
Free cash flow
-$47.09M
Per share
EPS
-$2.58
Free cash flow per share
-$1.81
Book value per share
$15.15
Revenue per share
$5.26
TBVPS
$12.32
Balance sheet
Total assets
$447.33M
Total liabilities
$48.18M
Debt
$13.31M
Equity
$399.15M
Working capital
$256.16M
Liquidity
Debt to equity
0.03
Current ratio
8.09
Quick ratio
7.84
Net debt/EBITDA
1.88
Margins
EBITDA margin
-42.6%
Gross margin
76.6%
Net margin
-49%
Operating margin
-66.5%
Efficiency
Return on assets
-14.9%
Return on equity
-16.5%
Return on invested capital
-69%
Return on capital employed
-16.8%
Return on sales
-50.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
0.54%
1 week
-0.62%
1 month
-4.54%
1 year
-50.98%
YTD
-4.38%
QTD
-4.38%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$137.04M
Gross profit
$105.03M
Operating income
-$91.14M
Net income
-$67.14M
Gross margin
76.6%
Net margin
-49%
The operating income has plunged by 127% YoY and by 10% from the previous quarter
The net income has dropped by 115% year-on-year and by 27% since the previous quarter
The operating margin has dropped by 56% year-on-year
The net margin has decreased by 47% YoY and by 14% QoQ

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
P/E
N/A
P/B
1.49
P/S
4.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.57
CSTL's EPS has dropped by 108% year-on-year and by 26% since the previous quarter
CSTL's price to book (P/B) is 22% lower than its last 4 quarters average of 1.9
The equity has declined by 3.1% year-on-year and by 3% since the previous quarter
CSTL's revenue is up by 46% YoY and by 11% from the previous quarter
The P/S is 36% below the last 4 quarters average of 6.7

Efficiency

How efficient is Castle Biosciences business performance
The ROE has shrunk by 120% YoY and by 28% QoQ
Castle Biosciences's return on assets has shrunk by 110% YoY and by 28% QoQ
Castle Biosciences's return on invested capital has surged by 68% YoY and by 32% QoQ
CSTL's return on sales is down by 18% year-on-year

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
Castle Biosciences's quick ratio has decreased by 44% YoY and by 14% QoQ
CSTL's current ratio is down by 43% year-on-year and by 14% since the previous quarter
The debt is 97% lower than the equity
The debt has soared by 65% YoY
CSTL's debt to equity has surged by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.